DDInter1627 DDInter822
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rufinamide {u} (Compound) binds {v} (Gene) SCN7A
SCN7A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rufinamide {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Glasdegib
Rufinamide (Compound) binds SCN7A (Gene) and SCN7A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Glasdegib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Glasdegib
Rufinamide (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Glasdegib